Andreas Meisel is an expert in Neurology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Andreas Meisel in the top 1% of experts worldwide for Muscle Weakness, Nervous System Neoplasms and Autoimmune Diseases. Andreas Meisel has authored 566 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 1 of them ongoing. SLR score: 2,426 (community average: 125). How the SLR is computed.

LeadR Profile

2 426 ScienceLeadR Reputation 2426
Network Map

Neurology

Subspecialties: Immunology - Hematology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Andreas Meisel is Professor of Neurology and Senior Physician at the Department of Neurology with Experimental Neurology and the Neuroscience Clinical Research Center at Charité – Universitätsmedizin Berlin. He serves as Director of the Center for Stroke Research Berlin and Head of the Integrated Myasthenia Gravis Center. He studied medicine at the Medical Faculty (Charité) of Humboldt University of Berlin and was an EMBO fellow at the Biozentrum of the University of Basel.

His group discovered the phenomenon of stroke-induced immunodepression. Research in his laboratory focuses on experimental and clinical neuroscience, with particular emphasis on cerebrovascular and neuromuscular disorders, immune mechanisms in stroke and myasthenic syndromes, biomarker-guided precision medicine, and the development of novel therapeutic and comprehensive care approaches. His team is actively engaged in translational research aimed at advancing individualized patient care.

Dr. Meisel is Chair of the Berlin Stroke Alliance, Chair of the Post-Stroke Care Commission of the German Stroke Society (DSG e.V.), Chair of the German Association for Research into Myasthenic Syndromes (VEMSID e.V.), and serves on the Medical Advisory Board of the German Myasthenia Society (DMG e.V.).

Organizations

Career arc: 1987 - 2026

Source: PubMed

Charité - University Medicine Berlin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 566

Citations

Citations: 27 271 1st author: 33 Last author: 144 Unique author: 48


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Stroke-associated pneumonia: from immunodepression to bedside management and future research directions.
PMID 42902359 — stroke, pneumonia, risk factors, diagnosis, research, therapeutics, deglutition disorders
Neurol Res Pract20260
Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper.
PMID 42717567 — complement c5, complement inactivating agents, immunotherapy, therapeutics, nervous system diseases, neurologists, myasthenia gravis
Eur J Neurol20260
Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).
PMID 42699831 — injections, activities of daily living, safety, therapeutics, myasthenia gravis
Front Neurol20260
Integrated B and T Cell Repertoire Analysis Reveals Organized but Heterogeneous Adaptive Immunity in Chronic Experimental Stroke.
PMID 42687874 — cells, genes, stroke, lymphocytes, adaptive immunity, immunoglobulins, immunity, sex, wounds and injuries, t-lymphocytes, b-lymphocytes
Res Sq20260
Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.
PMID 42624846 — cells, autoantibodies, biological science disciplines, receptors, cholinergic, antibodies, acetylcholine, myasthenia gravis, b-lymphocytes
Nat Commun20260

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 16

By phase:

N/A 18
Phase 3 9
Phase 2 3
Phase 1 1
Phase 4 1

By status:

Completed 21
Terminated 5
Unknown 3
Active not recruiting 2
Recruiting 1

By type:

Interventional 19
Observational 13

By Monocentric/Multicentric:

monocentric 16
multicentric2to4 2
multicentric5to9 3
multicentricup10 11

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858 — safety, muscles, pharmaceutical preparations, work, research, therapeutics, myasthenia gravis
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map